Midstage Study Results in Failure for Replimune Skin Cancer Therapy.

Published Date: 09 Dec 2023

On Tuesday, Replimune Group reported that a midstage study of its experimental combination therapy for common skin cancer had not shown any significant reduction or removal of cancerous lesions.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Short Shrift in Cancer Funding; Bypassing Familiar for Distant; Testing for BRCA.

2.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.

3.

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

4.

Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma

5.

Potential new therapy for childhood brain cancer could heal treatment-resistant tumors


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot